Androgen receptor: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 98: | Line 98: | ||
When a ligand promotes interactions between the N- and C-terminal AR domains, the AR is maximally active. The ability to reduce N/C interactions is the hallmark of SARMs that display antagonisms in androgenic tissues <ref name="SARMs knowledge" />. | When a ligand promotes interactions between the N- and C-terminal AR domains, the AR is maximally active. The ability to reduce N/C interactions is the hallmark of SARMs that display antagonisms in androgenic tissues <ref name="SARMs knowledge" />. | ||
====Diseases that could be treated with SARMs==== | ====Diseases that could be treated with SARMs==== | ||
SARMs may one day play a role in the treatment of cognitive disorders, such as '''Alzheimer's disease'''. Androgens facilitate the reduction of deleterious ß-amyloid (ßA) plaques, upregulating the expression of ßA-degrading neprilysin and | SARMs may one day play a role in the treatment of cognitive disorders, such as '''Alzheimer's disease'''. Androgens facilitate the reduction of deleterious ß-amyloid (ßA) plaques, upregulating the expression of ßA-degrading neprilysin and promoting synapse formation and neurogenesis, upregulating brain derived neurotrophic factor <ref name="Steroids" />. | ||
AR in '''breast cancer''' likely confers survival advantage by modulating ER signaling, which may reduce the risk of metastasis and aggressive disease. There is a clinical trial seeking to evaluate pembrolizumab and enobosarm co-therapy for the treatment of AR positive metastatic triple negative breast cancer <ref name="SARMs knowledge" />. | AR in '''breast cancer''' likely confers survival advantage by modulating ER signaling, which may reduce the risk of metastasis and aggressive disease. There is a clinical trial seeking to evaluate pembrolizumab and enobosarm co-therapy for the treatment of AR positive metastatic triple negative breast cancer <ref name="SARMs knowledge" />. | ||
'''Urinary incontinence''' denotes involuntary bladder urine leakage amongst women commonly with decreased pelvic muscle strength. As the pelvic floor muscles contain high levels of AR, it is a relevant target for SARM therapy <ref name="Steroids" />. | '''Urinary incontinence''' denotes involuntary bladder urine leakage amongst women commonly with decreased pelvic muscle strength. As the pelvic floor muscles contain high levels of AR, it is a relevant target for SARM therapy <ref name="Steroids" />. | ||
====Side effects==== | ====Side effects of SARMs==== | ||
Despite the consistent effect demonstrated by SARMs on lean body mass accrual, reductions in high-density lipoprotein (HDL) | Despite the consistent effect demonstrated by SARMs on lean body mass accrual, reductions in high-density lipoprotein (HDL) seem to be an important concern with these compounds, though it occurs to a lesser extent compared to testosterone <ref name="clinical trials">PMID: 32476495</ref>. | ||
SARMs administration has also been related to hepatotoxicity and some compounds have shown liver enzymes alterations | |||
SARMs administration has also been related to hepatotoxicity and some compounds have shown liver enzymes alterations. The most common adverse events are an increase in alanine transaminase and aspartate transaminase <ref name="clinical trials" />. | |||
The anabolic effects of SARMs and their lack of androgenic side effects have made them of great interest to the bodybuilding community and create the potential for abuse among competitive athletes <ref name="SARMs knowledge" />. | The anabolic effects of SARMs and their lack of androgenic side effects have made them of great interest to the bodybuilding community and create the potential for abuse among competitive athletes <ref name="SARMs knowledge" />. | ||
